Clinical Trials | December 23, 2025
Zambon Biotech launches European Phase 3b trial for innovative Parkinson’s drug
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
NUFYMCO BLA has been approved by the USFDA
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Subscribe To Our Newsletter & Stay Updated
